APA (7th ed.) Citation

N, K., A, G., S, R., J, S., A, F., A, S., . . . AM, F. (2024). Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry. European journal of haematology, 113(2), 235. https://doi.org/10.1111/ejh.14220

Chicago Style (17th ed.) Citation

N, Kutsch, et al. "Fludarabine, Cyclophosphamide, and Rituximab as First-line Treatment in Patients with Chronic Lymphocytic Leukemia: A Long-term Analysis of the German CLL Study Group (GCLLSG) Registry." European Journal of Haematology 113, no. 2 (2024): 235. https://doi.org/10.1111/ejh.14220.

MLA (9th ed.) Citation

N, Kutsch, et al. "Fludarabine, Cyclophosphamide, and Rituximab as First-line Treatment in Patients with Chronic Lymphocytic Leukemia: A Long-term Analysis of the German CLL Study Group (GCLLSG) Registry." European Journal of Haematology, vol. 113, no. 2, 2024, p. 235, https://doi.org/10.1111/ejh.14220.